Sequent Scientific is currently trading at Rs. 469.10, up by 11.35 points or 2.48 % from its previous closing of Rs. 457.75 on the BSE.
The scrip opened at Rs. 457.75 and has touched a high and low of Rs. 483.00 and Rs. 457.75 respectively. So far 19294 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 467.35 on 09-Sep-2014 and a 52 week low of Rs. 125.00 on 06-Dec-2013.
Last one week high and low of the scrip stood at Rs. 467.35 and Rs. 364.00 respectively. The current market cap of the company is Rs. 1287.49 crore.
The promoters holding in the company stood at 65.39 % while Institutions and Non-Institutions held 4.79 % and 29.82 % respectively.
Sequent Scientific’s wholly owned subsidiary, Alivira Animal Health (Alivira), has entered into an agreement to acquire 60% stake in Provet Veterinary Products, Turkey (Provet). The transaction is expected to close in October 2014, and is subject to customary closing conditions. The promoter of Provet is holding the balance 40% stake and will be part of the Management team at Alivira.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: